Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.

Abstract

We have previously demonstrated that individualized dosing of etoposide (VP16) by 72-hour infusion is feasible and that the extent of leukopenia is a function of plasma concentration, pretreatment WBC (WBCp), albumin (ALB), performance status (PS), and bone marrow function (based on transfusion requirements). In the current study, 45 patients were randomized between a fixed dose of VP16 (125 mg/m2/d) versus individualized dosing to a target WBC nadir (WBCN) of 1,700/microL. The total dose was increased by an average of 22% in the latter patients (459 +/- 130 mg/m2 v 375 mg/m2, P = .002). This was associated with a decrease in both the mean WBCN (1,510 +/- 950 v 2,500 +/- 1,420/microL, P = .013) and in the variability of the WBCN (P = .039). The VP16 clearance (mL/min) was not correlated with body surface area. Partial responses were observed in one patient each with hepatoma and non-Hodgkin's lymphoma. We conclude that pharmacologically based dosing may be a means of increasing dose intensity without increasing the incidence of life-threatening toxicity due to a decrease in variability around a target WBC.

0500'94'97'00'03'06'09'12'15
Citations per Year

4,022 Citations

Semantic Scholar estimates that this publication has 4,022 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Ratain1991PharmacologicallyBD, title={Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.}, author={Mark J. Ratain and Rosemarie Mick and Richard L. Schilsky and Nicholas J . Vogelzang and Frances Berezin}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={1991}, volume={9 8}, pages={1480-6} }